The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers
Active 5
  • 1
    Walsh, Patrick D.
    Director born in October 1960
    Individual (2 offsprings)
    Officer
    2024-10-31 ~ now
    OF - Director → CIF 0
    Walsh, Patrick
    Individual (2 offsprings)
    Officer
    2024-10-31 ~ now
    OF - Secretary → CIF 0
  • 2
    Parker, David John
    Private Equity born in August 1960
    Individual (5 offsprings)
    Officer
    2018-12-08 ~ now
    OF - Director → CIF 0
  • 3
    Wahlbrink, Trevor
    Private Equity born in August 1983
    Individual (2 offsprings)
    Officer
    2018-12-08 ~ now
    OF - Director → CIF 0
  • 4
    Hjerpe, Edward
    Director born in February 1991
    Individual (2 offsprings)
    Officer
    2024-06-27 ~ now
    OF - Director → CIF 0
  • 5
    Unit 3 Chancellor Court, 50 Occam Road, Surrey Research Park, Guildford, England
    Active Corporate (5 parents, 1 offspring)
    Profit/Loss (Company account)
    -7,990,695 GBP2023-01-01 ~ 2023-12-31
    Person with significant control
    2018-03-15 ~ now
    PE - Ownership of shares – 75% or more → CIF 0
    PE - Ownership of voting rights - 75% or more → CIF 0
    PE - Right to appoint or remove directors → CIF 0
Ceased 17
  • 1
    Kane, Michael
    President, Secretary And Treasurer born in November 1967
    Individual
    Officer
    2024-06-27 ~ 2024-10-31
    OF - Director → CIF 0
    Kane, Michael
    Individual
    Officer
    2024-06-27 ~ 2024-10-31
    OF - Secretary → CIF 0
  • 2
    Marriott, Christopher, Prof
    University Professor born in October 1944
    Individual (1 offspring)
    Officer
    2001-08-01 ~ 2009-05-20
    OF - Director → CIF 0
  • 3
    Nordsiek, Michael
    Pharmaceutical Development born in November 1958
    Individual
    Officer
    2013-09-25 ~ 2018-03-15
    OF - Director → CIF 0
  • 4
    Brown, Marc Barry, Prof
    Director born in June 1968
    Individual (6 offsprings)
    Officer
    1999-06-25 ~ 2024-01-17
    OF - Director → CIF 0
    Brown, Marc Barry
    Director
    Individual (6 offsprings)
    Officer
    1999-06-25 ~ 2005-06-30
    OF - Secretary → CIF 0
  • 5
    Murlewski, George David
    Director born in November 1955
    Individual (1 offspring)
    Officer
    2003-01-20 ~ 2008-01-17
    OF - Director → CIF 0
  • 6
    Muddle, Andrew Gordon, Dr
    Pharmaceutical Management born in April 1960
    Individual (3 offsprings)
    Officer
    1999-06-25 ~ 2024-01-17
    OF - Director → CIF 0
    Dr Andrew Gordon Muddle
    Born in April 1960
    Individual (3 offsprings)
    Person with significant control
    2016-04-06 ~ 2018-03-15
    PE - Ownership of shares – More than 25% but not more than 50% → CIF 0
    PE - Ownership of voting rights - More than 25% but not more than 50% → CIF 0
  • 7
    Sims, Malcolm Leslie
    Managing Director born in July 1946
    Individual
    Officer
    2001-08-01 ~ 2003-01-20
    OF - Director → CIF 0
  • 8
    Vernon, Geoffrey Nicholas, Dr
    Company Director born in March 1952
    Individual (5 offsprings)
    Officer
    2006-04-27 ~ 2013-08-30
    OF - Director → CIF 0
  • 9
    Freeman, George William
    Consultant born in July 1967
    Individual (3 offsprings)
    Officer
    2002-01-28 ~ 2002-07-01
    OF - Director → CIF 0
  • 10
    Martin, Gary Peter, Dr
    Director born in May 1954
    Individual
    Officer
    1999-06-25 ~ 2003-08-11
    OF - Director → CIF 0
  • 11
    Coleman, Maureen Sheila Helen
    Consultant born in April 1953
    Individual (7 offsprings)
    Officer
    2003-08-01 ~ 2005-10-27
    OF - Director → CIF 0
  • 12
    Ciolfi, Eugene Francis
    President & Ceo, Medpharm born in April 1966
    Individual
    Officer
    2021-09-13 ~ 2023-03-31
    OF - Director → CIF 0
  • 13
    Macdonald, Katie
    Individual (3 offsprings)
    Officer
    2005-06-30 ~ 2015-04-29
    OF - Secretary → CIF 0
  • 14
    Redgrove, Simon George
    Director born in May 1965
    Individual (16 offsprings)
    Officer
    2016-10-07 ~ 2018-05-01
    OF - Director → CIF 0
  • 15
    SHENLEY SECRETARIES LIMITED - now
    788-790 Finchley Road, London
    Active Corporate (1 parent, 85 offsprings)
    Equity (Company account)
    100 GBP2023-12-31
    Officer
    1999-06-07 ~ 1999-06-25
    PE - Nominee Secretary → CIF 0
  • 16
    788-790 Finchley Road, London
    Dissolved Corporate (2 parents, 22 offsprings)
    Officer
    1999-06-07 ~ 1999-06-25
    PE - Nominee Director → CIF 0
  • 17
    ENFRANCHISE SECRETARIAL SERVICES LIMITED - 1992-02-04
    125, Wood Street, London, England
    Active Corporate (6 parents, 215 offsprings)
    Equity (Company account)
    2 GBP2024-03-31
    Officer
    2015-07-14 ~ 2021-10-08
    PE - Secretary → CIF 0
parent relation
Company in focus

MEDPHARM LIMITED

Previous names
MEDFARM LIMITED - 1999-09-13
SUPA CONSULTING LIMITED - 1999-09-03
Standard Industrial Classification
72110 - Research And Experimental Development On Biotechnology
Brief company account
Average Number of Employees
942023-01-01 ~ 2023-12-31
1152022-01-01 ~ 2022-12-31
Turnover/Revenue
11,296,451 GBP2023-01-01 ~ 2023-12-31
18,676,309 GBP2022-01-01 ~ 2022-12-31
Cost of Sales
-13,155,706 GBP2023-01-01 ~ 2023-12-31
-17,613,492 GBP2022-01-01 ~ 2022-12-31
Gross Profit/Loss
-1,859,255 GBP2023-01-01 ~ 2023-12-31
1,062,817 GBP2022-01-01 ~ 2022-12-31
Administrative Expenses
-5,097,220 GBP2023-01-01 ~ 2023-12-31
-6,730,911 GBP2022-01-01 ~ 2022-12-31
Operating Profit/Loss
-6,945,218 GBP2023-01-01 ~ 2023-12-31
-5,356,901 GBP2022-01-01 ~ 2022-12-31
Other Interest Receivable/Similar Income (Finance Income)
4,670 GBP2023-01-01 ~ 2023-12-31
1,270 GBP2022-01-01 ~ 2022-12-31
Profit/Loss on Ordinary Activities Before Tax
-6,940,548 GBP2023-01-01 ~ 2023-12-31
-5,355,631 GBP2022-01-01 ~ 2022-12-31
Profit/Loss
-6,865,187 GBP2023-01-01 ~ 2023-12-31
-4,936,490 GBP2022-01-01 ~ 2022-12-31
Comprehensive Income/Expense
-6,902,293 GBP2023-01-01 ~ 2023-12-31
-5,715,373 GBP2022-01-01 ~ 2022-12-31
Property, Plant & Equipment
2,786,146 GBP2023-12-31
3,040,069 GBP2022-12-31
Fixed Assets - Investments
166,778 GBP2023-12-31
166,778 GBP2022-12-31
Fixed Assets
2,952,924 GBP2023-12-31
3,206,847 GBP2022-12-31
Total Inventories
50,281 GBP2023-12-31
60,642 GBP2022-12-31
Debtors
Current
4,037,527 GBP2023-12-31
5,943,624 GBP2022-12-31
Cash at bank and in hand
576,116 GBP2023-12-31
976,583 GBP2022-12-31
Current Assets
4,663,924 GBP2023-12-31
6,980,849 GBP2022-12-31
Creditors
Current, Amounts falling due within one year
-13,909,826 GBP2023-12-31
-9,578,381 GBP2022-12-31
Net Current Assets/Liabilities
-9,245,902 GBP2023-12-31
-2,597,532 GBP2022-12-31
Net Assets/Liabilities
-6,292,978 GBP2023-12-31
609,315 GBP2022-12-31
Equity
Called up share capital
10,025 GBP2023-12-31
10,025 GBP2022-12-31
10,025 GBP2022-01-01
Share premium
73,148 GBP2023-12-31
73,148 GBP2022-12-31
73,148 GBP2022-01-01
Capital redemption reserve
71 GBP2023-12-31
71 GBP2022-12-31
71 GBP2022-01-01
Other miscellaneous reserve
1,136,120 GBP2022-12-31
774,367 GBP2022-01-01
Retained earnings (accumulated losses)
-6,376,222 GBP2023-12-31
-610,049 GBP2022-12-31
5,105,324 GBP2022-01-01
Equity
-6,292,978 GBP2023-12-31
609,315 GBP2022-12-31
5,962,935 GBP2022-01-01
Profit/Loss
Retained earnings (accumulated losses)
-6,865,187 GBP2023-01-01 ~ 2023-12-31
-4,936,490 GBP2022-01-01 ~ 2022-12-31
Comprehensive Income/Expense
Retained earnings (accumulated losses)
-6,902,293 GBP2023-01-01 ~ 2023-12-31
-5,715,373 GBP2022-01-01 ~ 2022-12-31
Equity - Income/Expense Recognised Directly
Retained earnings (accumulated losses)
1,136,120 GBP2023-01-01 ~ 2023-12-31
Equity - Income/Expense Recognised Directly
361,753 GBP2022-01-01 ~ 2022-12-31
Audit Fees/Expenses
100,000 GBP2023-01-01 ~ 2023-12-31
110,000 GBP2022-01-01 ~ 2022-12-31
Wages/Salaries
3,624,691 GBP2023-01-01 ~ 2023-12-31
4,440,757 GBP2022-01-01 ~ 2022-12-31
Social Security Costs
354,948 GBP2023-01-01 ~ 2023-12-31
451,588 GBP2022-01-01 ~ 2022-12-31
Staff Costs/Employee Benefits Expense
4,151,698 GBP2023-01-01 ~ 2023-12-31
5,107,859 GBP2022-01-01 ~ 2022-12-31
Director Remuneration
72,002 GBP2023-01-01 ~ 2023-12-31
798,386 GBP2022-01-01 ~ 2022-12-31
Tax Expense/Credit at Applicable Tax Rate
-1,631,029 GBP2023-01-01 ~ 2023-12-31
-1,017,570 GBP2022-01-01 ~ 2022-12-31
Property, Plant & Equipment - Gross Cost
Plant and equipment
3,545,453 GBP2023-12-31
3,319,061 GBP2022-12-31
Furniture and fittings
335,378 GBP2023-12-31
326,365 GBP2022-12-31
Office equipment
540,279 GBP2023-12-31
508,252 GBP2022-12-31
Property, Plant & Equipment - Gross Cost
6,541,150 GBP2023-12-31
6,265,563 GBP2022-12-31
Property, Plant & Equipment - Accumulated Depreciation (Not Including Impairment)
Plant and equipment
2,219,477 GBP2022-12-31
Furniture and fittings
167,190 GBP2022-12-31
Office equipment
254,572 GBP2022-12-31
Property, Plant & Equipment - Accumulated Depreciation (Not Including Impairment)
3,225,494 GBP2022-12-31
Property, Plant & Equipment - Increase From Depreciation Charge for Year
Plant and equipment, Owned/Freehold
326,336 GBP2023-01-01 ~ 2023-12-31
Furniture and fittings, Owned/Freehold
23,183 GBP2023-01-01 ~ 2023-12-31
Office equipment, Owned/Freehold
45,515 GBP2023-01-01 ~ 2023-12-31
Owned/Freehold
529,510 GBP2023-01-01 ~ 2023-12-31
Property, Plant & Equipment - Accumulated Depreciation & Impairment
Plant and equipment
2,545,813 GBP2023-12-31
Furniture and fittings
190,373 GBP2023-12-31
Office equipment
300,087 GBP2023-12-31
Property, Plant & Equipment - Accumulated Depreciation & Impairment
3,755,004 GBP2023-12-31
Property, Plant & Equipment
Plant and equipment
999,640 GBP2023-12-31
1,099,584 GBP2022-12-31
Furniture and fittings
145,005 GBP2023-12-31
159,175 GBP2022-12-31
Office equipment
240,192 GBP2023-12-31
253,680 GBP2022-12-31
Raw materials and consumables
50,281 GBP2023-12-31
60,642 GBP2022-12-31
Trade Debtors/Trade Receivables
Current
1,355,256 GBP2023-12-31
2,511,034 GBP2022-12-31
Other Debtors
Current
617,152 GBP2023-12-31
1,242,556 GBP2022-12-31
Prepayments/Accrued Income
Current
2,065,119 GBP2023-12-31
2,190,034 GBP2022-12-31
Bank Overdrafts
-3,566 GBP2023-12-31
Cash and Cash Equivalents
572,550 GBP2023-12-31
976,583 GBP2022-12-31
Bank Overdrafts
Current
3,566 GBP2023-12-31
Trade Creditors/Trade Payables
Current
748,372 GBP2023-12-31
737,689 GBP2022-12-31
Amounts owed to group undertakings
Current
10,735,804 GBP2023-12-31
5,597,669 GBP2022-12-31
Taxation/Social Security Payable
Current
118,438 GBP2023-12-31
179,164 GBP2022-12-31
Other Creditors
Current
189,847 GBP2023-12-31
110,166 GBP2022-12-31
Accrued Liabilities/Deferred Income
Current
2,113,799 GBP2023-12-31
2,953,693 GBP2022-12-31
Creditors
Current
13,909,826 GBP2023-12-31
9,578,381 GBP2022-12-31
Number of Shares Issued (Fully Paid)
Class 1 ordinary share
423,000 shares2023-12-31
423,000 shares2022-12-31
Par Value of Share
Class 1 ordinary share
0.012023-01-01 ~ 2023-12-31
Number of Shares Issued (Fully Paid)
Class 2 ordinary share
408,200 shares2023-12-31
408,200 shares2022-12-31
Par Value of Share
Class 2 ordinary share
0.012023-01-01 ~ 2023-12-31
Number of Shares Issued (Fully Paid)
Class 3 ordinary share
171,300 shares2023-12-31
171,300 shares2022-12-31
Par Value of Share
Class 3 ordinary share
0.012023-01-01 ~ 2023-12-31
Future Minimum Lease Payments Under Non-cancellable Operating Leases
Amounts falling due within one year
342,340 GBP2023-12-31
313,227 GBP2022-12-31
Between one and five year
1,369,360 GBP2023-12-31
687,133 GBP2022-12-31
More than five year
770,265 GBP2023-12-31
Future Minimum Lease Payments Under Non-cancellable Operating Leases
2,481,965 GBP2023-12-31
1,000,360 GBP2022-12-31
  • MEDPHARM LIMITED
    Info
    MEDFARM LIMITED - 1999-09-13
    SUPA CONSULTING LIMITED - 1999-09-03
    Registered number 03783386
    Unit 3, Chancellor Court 50 Occam Road, Surrey Research Park, Guildford, Surrey GU2 7AB
    Private Limited Company incorporated on 1999-06-07 (26 years 4 months). The company status is Active.
    The last date of confirmation statement was made at 2024-06-07
    CIF 0
child relation
Offspring entities and appointments
Active 0
  • Not found in our database.

qrcode

Privacy notice

Terms and conditions

The content of this website is protected by AgonGuard.

© 2022-2025 Polylogarithmic Technology Ltd (Registered in England and Wales No. 14256313). All rights reserved.

Contains public sector information retrieved at 24 April 2025 and licensed under the Open Government Licence v3.0.